Androgen levels and metabolic parameters are associated with a genetic variant of F13A1 in women with polycystic ovary syndrome

Gene

Volumn 504, Issue 1, 2012, Pages 133-139

  Schweighofer, N ^a   Lerchbaum, E ^a   Trummer, O ^a   Schwetz, V ^a   Pilz, S ^a   Pieber, T R ^a   Obermayer Pietsch, B ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

HDL; Insulin resistance; PCOS; Testosterone

Indexed keywords

ANDROGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CASE CONTROL STUDY; CHEMICAL ANALYSIS; CHOLESTEROL BLOOD LEVEL; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; INSULIN RESISTANCE; INSULIN RESPONSE; INTRON; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANDROGENS; BODY COMPOSITION; BODY MASS INDEX; CASE-CONTROL STUDIES; COHORT STUDIES; FACTOR XIIIA; FEMALE; HUMANS; HYPERANDROGENISM; INSULIN RESISTANCE; OBESITY; POLYCYSTIC OVARY SYNDROME; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TESTOSTERONE;

EID: 84862325828     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.04.050     Document Type: Article

References (57)

1. Abbott D.H., Barnett D.K., Bruns C.M., Dumesic D.A. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome?. Hum. Reprod. Update 2005, 11(4):357-374.
2. Aboura A., et al. Array comparative genomic hybridization profiling analysis reveals deoxyribonucleic acid copy number variations associated with premature ovarian failure. J. Clin. Endocrinol. Metab. 2009, 94(11):4540-4546.
3. Allen T.L., Febbraio M.A. IL6 as a mediator of insulin resistance: fat or fiction?. Diabetologia 2010, 53:339-402.
4. American Diabetes Association Standards of medical care in diabetes-2008. Diabetes Care 2008, 31(Suppl. 1):S12-S54.
5. Barbieri R.L., Makris A., Ryan K.J. Insulin stimulates androgen accumulation in incubations of human ovarian stroma and theca. Obstet. Gynecol. 1984, 64(3 Suppl.):73 S-80 S.
6. Bereczky Z., et al. Modulation of the risk of coronary sclerosis/myocardial infarction by the interaction between factor XIII subunit A Val34Leu polymorphism and fibrinogen concentration in the high risk Hungarian population. Thromb. Res. 2007, 120(4):567-573.
7. Bremer A.A., Miller W.L. The serine phosphorylation hypothesis of polycystic ovary syndrome: a unifying mechanism for hyperandrogenemia and insulin resistance. Fertil. Steril. 2008, 89(5):1039-1048.
8. Carreras-Torres R., et al. Allele-allele interaction within the F13A1 gene: a risk factor for ischaemic heart disease in Spanish population. Thromb. Res. 2010, 126(3):e241-e245.
9. Castelo-Branco C., Steinvarcel F., Osorio A., Ros C., Balasch J. Atherogenic metabolic profile in PCOS patients: role of obesity and hyperandrogenism. Gynecol. Endocrinol. 2010, 26(10):736-742.
10. Coviello A.D., Sam S., Legro R.S., Dunaif A. High prevalence of metabolic syndrome in first-degree male relatives of women with polycystic ovary syndrome is related to high rates of obesity. J. Clin. Endocrinol. Metab. 2009, 94(11):4361-4366.
11. Dardik R., Loscalzo J., Eskaraev R., Inbal A. Molecular mechanisms underlying the proangiogenic effect of factor XIII. Arterioscler. Thromb. Vasc. Biol. 2005, 25(3):526-532.
12. Deligeoroglou E., Kouskouti C., Christopoulos P. The role of genes in the polycystic ovary syndrome: predisposition and mechanisms. Gynecol. Endocrinol. 2009, 25(9):603-609.
13. Diamanti-Kandarakis E., Piperi C. Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. Hum. Reprod. Update 2005, 11(6):631-643.
14. Diamanti-Kandarakis E., et al. Polycystic ovary syndrome: the influence of environmental and genetic factors. Hormones (Athens) 2006, 5(1):17-34.
15. Diamanti-Kandarakis E., Papavassiliou A.G., Kandarakis S.A., Chrousos G.P. Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol. Metab. 2007, 18(7):280-285.
16. Diamanti-Kandarakis E., Argyrakopoulou G., Economou F., Kandaraki E., Koutsilieris M. Defects in insulin signaling pathways in ovarian steroidogenesis and other tissues in polycystic ovary syndrome (PCOS). J. Steroid Biochem. Mol. Biol. 2008, 109(3-5):242-246.
17. Dunaif A., Segal K.R., Futterweit W., Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989, 38(9):1165-1174.
18. Escobar-Morreale H.F., Luque-Ramirez M., San Millan J.L. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr. Rev. 2005, 26(2):251-282.
19. Franks S., Gharani N., McCarthy M. Candidate genes in polycystic ovary syndrome. Hum. Reprod. Update 2001, 7(4):405-410.
20. Gilling-Smith C., Willis D.S., Beard R.W., Franks S. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J. Clin. Endocrinol. Metab. 1994, 79(4):1158-1165.
21. Gilling-Smith C., Story H., Rogers V., Franks S. Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin. Endocrinol. (Oxf.) 1997, 47(1):93-99.
22. Govind A., Obhrai M.S., Clayton R.N. Polycystic ovaries are inherited as an autosomal dominant trait: analysis of 29 polycystic ovary syndrome and 10 control families. J. Clin. Endocrinol. Metab. 1999, 84(1):38-43.
23. Graupp M., Wehr E., Schweighofer N., Pieber T.R., Obermayer-Pietsch B. Association of genetic variants in the two isoforms of 5alpha-reductase, SRD5A1 and SRD5A2, in lean patients with polycystic ovary syndrome. Eur. J. Obstet. Gynecol. Reprod. Biol. 2011, 157(2):175-179.
24. Greco D., et al. Gene expression in human NAFLD. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 294(5):G1281-G1287.
25. Hatch R., Rosenfield R.L., Kim M.H., Tredway D. Hirsutism: implications, etiology, and management. Am. J. Obstet. Gynecol. 1981, 140(7):815-830.
26. Ichinose A., Davie E.W. Characterization of the gene for the a subunit of human factor XIII (plasma transglutaminase), a blood coagulation factor. Proc. Natl. Acad. Sci. U. S. A. 1988, 85(16):5829-5833.
27. Ingram C.J., Mulcare C.A., Itan Y., Thomas M.G., Swallow D.M. Lactose digestion and the evolutionary genetics of lactase persistence. Hum. Genet. 2009, 124(6):579-591.
28. Kurzrock R., Cohen P.R. Polycystic ovary syndrome in men: Stein-Leventhal syndrome revisited. Med. Hypotheses 2007, 68:480-483.
29. Laurila P.P., et al. Genome-wide association analysis and expression analysis from adipose tissue reveals coagulation factor XIII as a novel candidate gene for low HDL-cholesterol. Eur. J. Hum. Genet. 2009, 17(Suppl. 2):28.
30. Legro R.S., Kunselman A.R., Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am. J. Med. 2001, 111(8):607-613.
31. Legro R.S., Castracane V.D., Kauffman R.P. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet. Gynecol. Surv. 2004, 59(2):141-154.
32. Lei S., et al. Bivariate whole-genome linkage scan for bone geometry and total body fat mass. J. Genet. Genomics 2009, 36(2):89-97.
33. Lerchbaum E., Trummer O., Giuliani A., Gruber H.J., Pieber T.R., Obermayer-Pietsch B. Susceptibility Loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21, and 9q33.3 in a cohort of Caucasian women. Horm. Metab. Res. 2011, 43(11):743-747.
34. Loof T.G., et al. Coagulation, an ancestral serine protease cascade, exerts a novel function in early immune defense. Blood 2011, 118(9):2589-2598.
35. Maitra A., Pingle R.R., Menon P.S., Naik V., Gokral J.S., Meherji P.K. Dyslipidemia with particular regard to apolipoprotein profile in association with polycystic ovary syndrome: a study among Indian women. Int. J. Fertil. Womens Med. 2001, 46(5):271-277.
36. Marin F., et al. Factor XIII Val34Leu polymorphism modulates the prothrombotic and inflammatory state associated with atrial fibrillation. J. Mol. Cell. Cardiol. 2004, 37:699-704.
37. Mhawech-Fauceglia P., et al. Array-comparative genomic hybridization analysis of primary endometrial and ovarian high-grade neuroendocrine carcinoma associated with adenocarcinoma: mystery resolved?. Int. J. Gynecol. Pathol. 2008, 27(4):539-546.
38. Middelberg R.P., et al. Linkage and association analyses of longitudinally measured lipid phenotypes in adolescence. Twin Res. Hum. Genet. 2008, 11(6):603-620.
39. Minamino T., et al. A crucial role for adipose tissue p53 in the regulation of insulin resistance. Nat. Med. 2009, 15(9):1082-1088.
40. Mukherjee S., Maitra A. Molecular & genetic factors contributing to insulin resistance in polycystic ovary syndrome. Indian J. Med. Res. 2010, 131:743-760.
41. Muszbek L., Bagoly Z., Bereczky Z., Katona E. The involvement of blood coagulation factor XIII in fibrinolysis and thrombosis. Cardiovasc. Hematol. Agents Med. Chem. 2008, 6(3):190-205.
42. Naukkarinen J., et al. Use of genome-wide expression data to mine the "Gray Zone" of GWA studies leads to novel candidate obesity genes. PLoS Genet. 2010, 6(6):e1000976.
43. Nisenblat V., Norman R.J. Androgens and polycystic ovary syndrome. Curr. Opin. Endocrinol. Diabetes Obes. 2009, 16(3):224-231.
44. Poretsky L., Cataldo N.A., Rosenwaks Z., Giudice L.C. The insulin-related ovarian regulatory system in health and disease. Endocr. Rev. 1999, 20(4):535-582.
45. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum. Reprod. 2004, 19(1):41-47. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group.
46. Sarzani R., Salvi F., Dessi-Fulgheri P., Rappelli A. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J. Hypertens. 2008, 26(5):831-843.
47. Shen N., Yu X., Pan F.-Y., Gao X., Xue B., Li C.-J. An early response transcription factor, Egr-1, enhances insulin resistance in type 2 diabetes with chronic hyperinsulinism. J. Biol. Chem. 2011, 286(16):14508-14515.
48. Soler J.T., Folsom A.R., Kaye S.A., Prineas R.J. Associations of abdominal adiposity, fasting insulin, sex hormone binding globulin, and estrone with lipids and lipoproteins in post-menopausal women. Atherosclerosis 1989, 79(1):21-27.
49. Tsujimoto I., Moriya K., Sakai K., Dickneite G., Sakai T. Critical role of factor XIII in the initial stages of carbon tetrachloride-induced adult liver remodelling. Am. J. Pathol. 2011, 179(6):3011-3019.
50. Valkenburg O., et al. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. J. Clin. Endocrinol. Metab. 2008, 93(2):470-476.
51. Wang H.S., Wang T.H. Polycystic ovary syndrome (PCOS), insulin resistance and insulin-like growth factors (IGfs)/IGF-binding proteins (IGFBPs). Chang Gung Med. J. 2003, 26(8):540-553.
52. Warner D., Mansfield M.W., Grant P.J. Coagulation factor XIII and cardiovascular disease in UK Asian patients undergoing coronary angiography. Thromb. Haemost. 2001, 85(3):408-411.
53. Westerveld H.E., Hoogendoorn M., de Jong A.W., Goverde A.J., Fauser B.C., Dallinga-Thie G.M. Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights. Pharmacol. Ther. 2008, 119(3):223-241.
54. Wu Z.Y., Wu X.K., Zhang Y.W. Relationship of menopausal status and sex hormones to serum lipids and blood pressure. Int. J. Epidemiol. 1990, 19(2):297-302.
55. Yilmaz M., et al. Glucose intolerance, insulin resistance and cardiovascular risk factors in first degree relatives of women with polycystic ovary syndrome. Hum. Reprod. 2005, 20(9):2414-2420.
56. Yu X., et al. Egr-1 decreases adipocyte insulin sensitivity by tilting PI3K/Akt and MAPK signal balance in mice. EMBO J. 2011, 30:3754-3765.
57. Zang H., Carlstrom K., Arner P., Hirschberg A.L. Effects of treatment with testosterone alone or in combination with estrogen on insulin sensitivity in postmenopausal women. Fertil. Steril. 2006, 86(1):136-144.